MK-8745

Aurora A inhibitor,potent and selective CAS# 885325-71-3

MK-8745

Catalog No. BCC3994----Order now to get a substantial discount!

Product Name & Size Price Stock
MK-8745: 5mg $35 In Stock
MK-8745: 10mg Please Inquire In Stock
MK-8745: 20mg Please Inquire Please Inquire
MK-8745: 50mg Please Inquire Please Inquire
MK-8745: 100mg Please Inquire Please Inquire
MK-8745: 200mg Please Inquire Please Inquire
MK-8745: 500mg Please Inquire Please Inquire
MK-8745: 1000mg Please Inquire Please Inquire
Related Products
  • MLN8237 (Alisertib)

    Catalog No.:BCC2166
    CAS No.:1028486-01-2
  • SCH-1473759

    Catalog No.:BCC1934
    CAS No.:1094069-99-4
  • Reversine

    Catalog No.:BCC1892
    CAS No.:656820-32-5
  • AZD1152

    Catalog No.:BCC1393
    CAS No.:722543-31-9
  • XL228

    Catalog No.:BCC2058
    CAS No.:898280-07-4

Quality Control of MK-8745

Number of papers citing our products

Chemical structure

MK-8745

3D structure

Chemical Properties of MK-8745

Cas No. 885325-71-3 SDF Download SDF
PubChem ID 11676373 Appearance Powder
Formula C20H19ClFN5OS M.Wt 431.91
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (231.53 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (3-chloro-2-fluorophenyl)-[4-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]piperazin-1-yl]methanone
SMILES C1CN(CCN1CC2=NC(=CC=C2)NC3=NC=CS3)C(=O)C4=C(C(=CC=C4)Cl)F
Standard InChIKey YCRFPWKUUNKNDN-UHFFFAOYSA-N
Standard InChI InChI=1S/C20H19ClFN5OS/c21-16-5-2-4-15(18(16)22)19(28)27-10-8-26(9-11-27)13-14-3-1-6-17(24-14)25-20-23-7-12-29-20/h1-7,12H,8-11,13H2,(H,23,24,25)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of MK-8745

DescriptionMK-8745 is a potent and selective inhibitor of Aurora A with an IC50 value of 0.6 nM.
TargetsAurora A    
IC500.6 nM     

MK-8745 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

MK-8745 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of MK-8745

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3153 mL 11.5765 mL 23.153 mL 46.3059 mL 57.8824 mL
5 mM 0.4631 mL 2.3153 mL 4.6306 mL 9.2612 mL 11.5765 mL
10 mM 0.2315 mL 1.1576 mL 2.3153 mL 4.6306 mL 5.7882 mL
50 mM 0.0463 mL 0.2315 mL 0.4631 mL 0.9261 mL 1.1576 mL
100 mM 0.0232 mL 0.1158 mL 0.2315 mL 0.4631 mL 0.5788 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on MK-8745

MK-8745 is a novel and selective inhibitor of Aurora A with IC50 value of 0.6 nM [1].

Aurora A kinase is a member of mitotic serine/threonine kinases and plays an important role in cellular division by controlling chromatid segregation. It has been reported that abnormal expression of Aurora A is correlated with the high occurrence of cancer and its expression determines cell sensitivity to MK-8745 treatment [1].

MK-8745 is a potent Aurora A inhibitor. When tested with p53-/+ cell lines, MK-8745 treatment induced apoptotic cell death in a p53-dependent manner through inhibiting Aurora A activity [1]. In non-Hodgkin lymphoma (NHL) cell lines, MK-8745 treatment arrested cell cycle in G2/M phase and induced cell death via inhibiting Aurora A kinase [2]. In HCT 116 Puma (-), HCT116 p21 (-), HCT116 Bax(-) and HCT116 Chk2(-) cell lines, MK-8745 treatment induced cell apoptosis with the percent of 25%, 22%, 25%, and 22%, respectively [3].

In female athymic nude mice model subcutaneous xenografted with HCT116 Puma (-), HCT116 p21 (-), HCT116 Bax(-) and HCT116 Chk2(-) cells, administration of MK-8745 significantly inhibited tumor growth [3].

References:
[1].  Nair, J.S., A.L. Ho, and G.K. Schwartz, The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle, 2012. 11(4): p. 807-17.
[2].  Chowdhury, A., S. Chowdhury, and M.Y. Tsai, A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma, 2012. 53(3): p. 462-71.
[3].   Shionome, Y., et al., Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors. PLoS One, 2013. 8(1): p. e55457.

Featured Products
New Products
 

References on MK-8745

A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.[Pubmed:21879811]

Leuk Lymphoma. 2012 Mar;53(3):462-71.

Selective small-molecule kinase inhibitors have encouraging clinical efficacy in several malignancies. These agents are still limited to a subset of patients, indicating the need to develop therapeutic biomarkers that influence clinical benefit. In this study, we demonstrate that treatment with MK-8745, a novel Aurora-A specific inhibitor, leads to cell cycle arrest at the G2/M phase with accumulation of tetraploid nuclei followed by cell death in non-Hodgkin lymphoma (NHL) cell lines. The sensitivity of the cell lines to MK-8745 is correlated with the expression level of Aurora-A activator. The siRNA knockdown of Aurora-A activator TPX2 (targeting protein for Xenopus kinase-like protein 2) increased MK-8745 sensitivity in less-MK-8745-sensitive NHL cell lines, whereas overexpression of TPX2 in high-MK-8745-sensitive NHL cell lines increased drug resistance. Our results indicate that TPX2 may serve as a biomarker for identifying subpopulations of patients sensitive to Aurora-A inhibitor treatment.

Description

MK-8745 is an aurora A kinase inhibitor with an IC50 of 0.6 nM.

Keywords:

MK-8745,885325-71-3,Natural Products,Aurora Kinase, buy MK-8745 , MK-8745 supplier , purchase MK-8745 , MK-8745 cost , MK-8745 manufacturer , order MK-8745 , high purity MK-8745

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: